AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine, or ELAHERE, for the treatment of adult patients with folate receptor alpha-positive, platinum-resistant and high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior treatment regimens. The European Commission decision on this indication for mirvetuximab soravtansine is anticipated later in the current year.
ELAHERE was granted full FDA approval in March 2024. The CHMP's opinion is supported by results of the Phase 3 MIRASOL clinical trial.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.